HRP20160802T1 - Čvrsti farmaceutski pripravci koji sadrže derivate biopterina i upotreba takvih pripravaka - Google Patents

Čvrsti farmaceutski pripravci koji sadrže derivate biopterina i upotreba takvih pripravaka Download PDF

Info

Publication number
HRP20160802T1
HRP20160802T1 HRP20160802TT HRP20160802T HRP20160802T1 HR P20160802 T1 HRP20160802 T1 HR P20160802T1 HR P20160802T T HRP20160802T T HR P20160802TT HR P20160802 T HRP20160802 T HR P20160802T HR P20160802 T1 HRP20160802 T1 HR P20160802T1
Authority
HR
Croatia
Prior art keywords
pharmaceutical preparation
compound
image
formula
phosphate
Prior art date
Application number
HRP20160802TT
Other languages
English (en)
Croatian (hr)
Inventor
Frank Tegtmeier
Reinhard Schinzel
Peter Scheurer
Original Assignee
Vasopharm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vasopharm Gmbh filed Critical Vasopharm Gmbh
Publication of HRP20160802T1 publication Critical patent/HRP20160802T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HRP20160802TT 2014-03-31 2016-07-06 Čvrsti farmaceutski pripravci koji sadrže derivate biopterina i upotreba takvih pripravaka HRP20160802T1 (hr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14162727.3A EP2926805B1 (en) 2014-03-31 2014-03-31 Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions

Publications (1)

Publication Number Publication Date
HRP20160802T1 true HRP20160802T1 (hr) 2016-08-12

Family

ID=50389975

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20160802TT HRP20160802T1 (hr) 2014-03-31 2016-07-06 Čvrsti farmaceutski pripravci koji sadrže derivate biopterina i upotreba takvih pripravaka

Country Status (28)

Country Link
US (7) US9895372B2 (enExample)
EP (2) EP2926805B1 (enExample)
JP (3) JP6552515B2 (enExample)
KR (1) KR102374500B1 (enExample)
CN (2) CN113521017A (enExample)
AU (2) AU2015239736B2 (enExample)
CA (1) CA2938267C (enExample)
CL (1) CL2016002463A1 (enExample)
CY (1) CY1117881T1 (enExample)
DK (1) DK2926805T3 (enExample)
ES (1) ES2586945T3 (enExample)
HR (1) HRP20160802T1 (enExample)
HU (1) HUE030221T2 (enExample)
IL (1) IL248090B (enExample)
MX (1) MX377919B (enExample)
MY (1) MY180844A (enExample)
PE (1) PE20161253A1 (enExample)
PH (1) PH12016501519B1 (enExample)
PL (1) PL2926805T3 (enExample)
PT (1) PT2926805T (enExample)
RS (1) RS54973B1 (enExample)
RU (1) RU2694368C2 (enExample)
SA (1) SA516371933B1 (enExample)
SG (1) SG11201606151SA (enExample)
SI (1) SI2926805T1 (enExample)
SM (1) SMT201600246B (enExample)
WO (1) WO2015150294A1 (enExample)
ZA (1) ZA201605271B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9499532B2 (en) 2014-02-07 2016-11-22 eXIthera Pharmaceuticals Inc. Therapeutic compounds and compositions
PL2926805T3 (pl) * 2014-03-31 2016-12-30 Stałe kompozycje farmaceutyczne zawierające pochodne biopteryny oraz zastosowania takich kompozycji
JP2016168783A (ja) * 2015-03-13 2016-09-23 株式会社東芝 記録装置、記録方法、及び記録媒体
US12171766B2 (en) 2021-12-03 2024-12-24 Verinos Operations Gmbh Methods of treating patients suffering from brain injury and methods of increasing the value of the extended Glasgow Outcome Scale of patients suffering from brain injury
CA3073957A1 (en) * 2017-09-01 2019-03-07 Censa Pharmaceuticals Inc. Pharmaceutical compositions comprising sepiapterin and uses thereof
JP6565103B2 (ja) * 2017-09-06 2019-08-28 株式会社昭和冷凍プラント 香気成分含有水溶液を含む液状製品の製造方法
IL291565B1 (en) * 2019-09-25 2026-04-01 Ptc Therapeutics Inc Method for treating phenylalanine irregularity
EP4440578A1 (en) 2021-12-03 2024-10-09 VeriNOS operations GmbH Methods of treating patients suffering from brain injury and methods of increasing the value of the extended glasgow outcome scale of patients suffering from brain injury
TW202406555A (zh) 2022-05-06 2024-02-16 德商veriNOS運營有限公司 治療患有與增加的麩胺酸水平相關的疾病狀況或病症的患者的方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922713A (en) * 1997-06-26 1999-07-13 Werner; Ernst Inhibition of nitric oxide synthase
DE59703603D1 (de) 1997-10-06 2001-06-28 Ernst Werner Pteridinderivate als NO Synthase-Hemmer
US6803046B2 (en) * 2002-08-16 2004-10-12 Bracco International B.V. Sincalide formulations
WO2005037286A1 (en) * 2003-03-25 2005-04-28 Vasopharm Biotech Gmbh Use of pteridine derivatives for the treatment of increased intracranial pressure and secondary ischemia
CN1894251B (zh) * 2003-11-17 2011-06-29 默克和西伊公司 (6r)-l-赤型-四氢生物蝶呤二盐酸盐的晶型
WO2005107759A1 (ja) * 2004-05-11 2005-11-17 Daiichi Asubo Pharma Co., Ltd. Bh4反応性高フェニルアラニン血症治療剤
SE0401826D0 (sv) 2004-07-09 2004-07-09 Trimble Ab Method of preparing a winding for an n-phase motor
BRPI0517088A (pt) * 2004-11-17 2008-09-30 Biomarin Pharm Inc formulação de comprimido estável
EP1669355A1 (en) * 2004-12-02 2006-06-14 Vasopharm Biotech GmbH Aminotetrahydropteridines and processes for manufacture thereof
SI3461503T1 (sl) 2007-04-11 2022-04-29 Biomarin Pharmaceutical Inc. Postopki za dajanje tetrahidrobiopterina, povezani sestavki in postopki merjenja
WO2008128576A2 (de) 2007-04-24 2008-10-30 Osram Gesellschaft mit beschränkter Haftung Schaltungsanordnung zur zündung und zum betrieb einer entladungslampe
US20110144117A1 (en) 2008-08-12 2011-06-16 Orpha Swiss Gmbh Pharmaceutical Dosage Form Containing Tetrahydrobiopterin
KR20140021585A (ko) * 2011-03-01 2014-02-20 루비콘 리서치 피브이티. 엘티디. 테트라하이드로바이옵테린의 안정한 조성물
EP2750664A1 (en) * 2011-08-30 2014-07-09 Fresenius Kabi USA, LLC Levothyroxine formulations
PL2926805T3 (pl) * 2014-03-31 2016-12-30 Stałe kompozycje farmaceutyczne zawierające pochodne biopteryny oraz zastosowania takich kompozycji

Also Published As

Publication number Publication date
JP2021105062A (ja) 2021-07-26
PT2926805T (pt) 2016-07-15
RU2016141449A3 (enExample) 2018-12-14
US11717522B2 (en) 2023-08-08
MX377919B (es) 2025-03-10
MX2016012784A (es) 2017-04-25
CL2016002463A1 (es) 2017-01-27
US9895372B2 (en) 2018-02-20
BR112016020101A2 (enExample) 2017-07-15
ZA201605271B (en) 2017-08-30
PH12016501519A1 (en) 2017-02-06
JP2019194227A (ja) 2019-11-07
AU2015239736B2 (en) 2020-03-26
US20210137927A1 (en) 2021-05-13
US20220031703A9 (en) 2022-02-03
ES2586945T3 (es) 2016-10-19
EP2926805A1 (en) 2015-10-07
DK2926805T3 (en) 2016-07-25
AU2020203880B2 (en) 2022-03-31
SMT201600246B (it) 2016-08-31
IL248090A0 (en) 2016-11-30
US12458644B2 (en) 2025-11-04
MY180844A (en) 2020-12-10
US20200046710A1 (en) 2020-02-13
RS54973B1 (sr) 2016-11-30
CA2938267C (en) 2023-05-09
NZ722455A (en) 2022-03-25
US10493075B2 (en) 2019-12-03
PL2926805T3 (pl) 2016-12-30
AU2015239736A1 (en) 2016-08-11
BR112016020101A8 (pt) 2021-06-29
RU2016141449A (ru) 2018-05-07
HK1213195A1 (en) 2016-06-30
KR20160138406A (ko) 2016-12-05
HUE030221T2 (en) 2017-04-28
CN113521017A (zh) 2021-10-22
AU2020203880A1 (en) 2020-07-02
JP2017509623A (ja) 2017-04-06
US20230355630A1 (en) 2023-11-09
CY1117881T1 (el) 2018-03-07
EP2926805B1 (en) 2016-05-18
EP3125864A1 (en) 2017-02-08
US20260048056A1 (en) 2026-02-19
JP7178731B2 (ja) 2022-11-28
US20170296543A1 (en) 2017-10-19
IL248090B (en) 2019-10-31
CN106572976A (zh) 2017-04-19
JP6552515B2 (ja) 2019-07-31
WO2015150294A1 (en) 2015-10-08
SI2926805T1 (sl) 2016-09-30
SA516371933B1 (ar) 2019-04-14
CA2938267A1 (en) 2015-10-08
PH12016501519B1 (en) 2017-02-06
PE20161253A1 (es) 2016-11-13
JP6879582B2 (ja) 2021-06-02
US10925877B2 (en) 2021-02-23
SG11201606151SA (en) 2016-08-30
US20180289714A1 (en) 2018-10-11
KR102374500B1 (ko) 2022-03-15
US10016431B2 (en) 2018-07-10
RU2694368C2 (ru) 2019-07-12
US20170112836A1 (en) 2017-04-27

Similar Documents

Publication Publication Date Title
HRP20180007T1 (hr) Formulacija koja sadrži gemcitabin-predlijek
SG10201804024VA (en) Formulations of azaindole compounds
EA201291348A1 (ru) Активаторы растворимой гуанилатциклазы
JP2017509623A5 (enExample)
RU2017134002A (ru) Стабильные композиции тетрагидробиоптерина
HRP20191285T1 (hr) Predlijekovi karbidopa i l-dopa te njihova uporaba za liječenje parkinsonove bolesti
BR112017010551A2 (pt) composto, métodos para ativação de guanilato ciclase solúvel, para tratamento de uma ou mais condições selecionadas a partir de uma doença em um paciente e para tratamento de uma doença ou condição, composição farmacêutica, uso de um composto, e, medicamento.
HRP20211278T1 (hr) Supstituirani derivati indolina kao inhibitori replikacije denga virusa
HRP20140011T1 (hr) Derivati oksazina i njihova uporaba u lijeäśenju neuroloških poremeä†aja
HRP20200196T1 (hr) Fiziološki balansirane injektabilne formulacije fosnetupitanta
JP2016534142A5 (enExample)
RU2016141449A (ru) Твердые фармацевтические композиции, содержащие производные биоптерина, и способы применения таких композиций
BR112015020823A8 (pt) 1-hidróxi-benzooxaboróis como agentes antiparasíticos, seus usos, e formulação".
EA201691490A1 (ru) Фармацевтическая композиция, содержащая бринзоламид
AR105203A1 (es) Formulación oral sólida que contiene irinotecán y método de preparación de la misma
HRP20240166T1 (hr) Postupak liječenja prader-willijevog sindroma
ME02405B (me) Spojevi pirazola као inhibitori sglt1
MX2016001422A (es) Composicion farmaceutica de fingolimod.
HRP20210010T1 (hr) Injekcijske farmaceutske formulacije lefamulina
JP2015526463A5 (enExample)
RU2016121401A (ru) Устойчивые при хранении лиофилизованные составы трипептидов
HRP20211761T1 (hr) Dvokomponentna kompozicija koja sadrži acetilsalicilnu kiselinu
HRP20210418T1 (hr) Liječenje s syd985 pacijenata s rakom koji ne reagira na t-dm1
RU2015145451A (ru) Препараты для местного применения, содержащие гиалуроновую кислоту, вербаскозид и глицерофосфоинозитол
HRP20201598T1 (hr) Pripravci